Now bankrupt, Zosano sells off its drug delivery tech that once enticed Novo Nordisk, Eli Lilly

Amber Tong

Closing out the final chapter of its winding 16-year history, Zosano Pharma has sold all of its remaining assets — including the intradermal drug delivery system …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Now bankrupt, Zosano sells off its drug delivery tech that once enticed Novo Nordisk, Eli Lilly

Amber Tong

Sign up to read this article for free.

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Now bank­rupt, Zosano sells off its drug de­liv­ery tech that once en­ticed No­vo Nordisk, Eli Lil­ly

Amber Tong

Sign up to read this article for free.

more like this

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Now bankrupt, Zosano sells off its drug delivery tech that once enticed Novo Nordisk, Eli Lilly

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Soleno’s rare pediatric disease drug faces PDUFA delay by three months